Home
Resources
Publications
Gelatin-albumin Hybrid Nanoparticles as Matrix Metalloproteinases-Degradable Delivery Systems for Breast Cancer Therapy

Gelatin-albumin Hybrid Nanoparticles as Matrix Metalloproteinases-Degradable Delivery Systems for Breast Cancer Therapy

Vahid Heravi Shargh, Hubert Hondermarck, Mingtao Liang

Nanomedicine (Lond). 2017 May;12(9):977-989.

PMID: 28440712

Abstract:

Aim:
To develop matrix metalloproteinase-responsive gelatin-albumin hybrid nanoparticles encapsulating a selective tropomyosin receptor kinase A (TrkA) inhibitor GNF-5837 (Gel-Alb-GNF HNPs) and to demonstrate their anticancer effects in breast cancer.
Methods:
Gel-Alb-GNF HNPs were prepared using a pH-controlled complexation process from cationic gelatin, dextran sulfate and albumin-bound GNF-5837. The anticancer activities of Gel-Alb-GNF HNPs were tested in a panel of subtype-specific breast cancer cell lines.
Results:
Gel-Alb-GNF HNPs (∼130 nm) displayed excellent stability and matrix metalloproteinase-triggered drug release. Compared with GNF-5837 alone, Gel-Alb-GNF HNPs not only significantly enhanced the antiproliferative and anti-invasive effects but also restored the apoptosis of cancer cells.
Conclusion:
Gel-Alb-GNF HNPs may be adaptable for stand-alone therapies or used in combination with traditional chemotherapies for breast cancer treatment.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1033769286-A	GNF 5837		1033769-28-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: